A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8).

Authors

• William Kelly

Publication/Presentation Date

2-2019

Volume

37

Issue

7

Published In/Presented At

DOI: 10.1200/JCO.2019.37.7_suppl.TPS329

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article